Astrazeneca (AZN)

 

Latest News

Metal price recovery pushes FTSE higher

Metal prices bounced back on Friday, helping the mining sector rise throughout the morning. Fresnillo (FRES) enjoyed gai...

AstraZeneca gets approvals in Japan

AstraZeneca has received approvals in Japan for treatments of asthma and ovarian cancer. AstraZeneca and its global bio...

Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC

Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and set its price target ...

Broker Forecast - Exane BNP Paribas issues a broker note on AstraZeneca PLC

Exane BNP Paribas today reaffirms its outperform investment rating on AstraZeneca PLC (LON:AZN) and set its price ta...

All News

DateHeadlineSource
19-01-18Metal price recovery pushes FTSE higher StockMarketWire
19-01-18AstraZeneca gets approvals in JapanStockMarketWire
16-01-18Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLCStockMarketWire
16-01-18Broker Forecast - Exane BNP Paribas issues a broker note on AstraZeneca PLCStockMarketWire
12-01-18FDA approves Lynparza for metastatic breast cancerRNS
12-01-18David Buik's stocks to follow in 2018Interactive Investor
11-01-18Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLCStockMarketWire
10-01-18AstraZeneca's Fasenra approved in the EURNS
02-01-18Total Voting RightsRNS
28-12-17Director/PDMR ShareholdingRNS
27-12-17These UK stocks are among the best in EuropeInteractive Investor
18-12-17FTSE 100 follows US higher StockMarketWire
18-12-17AstraZeneca lung cancer drug granted priority review in USStockMarketWire
18-12-17FDA accepts Tagrisso submission for 1st-line nsclcRNS
15-12-17Director Deals - AstraZeneca PLC (AZN)StockMarketWire
15-12-17Director/PDMR ShareholdingRNS
05-12-17Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLCStockMarketWire
01-12-17Total Voting RightsRNS
01-12-17Block listing Interim ReviewRNS
28-11-17EMA accepts Tagrisso submission for 1st-line nsclcRNS
27-11-17FTSE falls as copper price declinesStockMarketWire
27-11-17Chart of the week: A low-risk blue-chip 'buy'Interactive Investor
27-11-17FTSE rises as Glaxo gets shot in the armStockMarketWire
27-11-17AZ submits Tagrisso application in Japan StockMarketWire
27-11-17AZ submits Tagrisso in Japan for 1st-line nsclcRNS
16-11-17Broker Forecast - HSBC issues a broker note on AstraZeneca PLCStockMarketWire
15-11-17 AZ Fasenra gets FDA approval for severe asthmaStockMarketWire
15-11-17AZ Fasenra receives FDA approval for severe asthmaRNS
10-11-17AstraZeneca receives positive EU CHMP opinion for asthma treatmentStockMarketWire
10-11-17BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMARNS
09-11-17FTSE 100 dips after weak Wall Street tradingStockMarketWire
09-11-17AstraZeneca operating profits rise StockMarketWire
09-11-17AZN: Year-To-Date and Q3 2017 Results AnnouncementRNS
08-11-17How I am preparing for a stockmarket correctionInteractive Investor
03-11-17Have Neil Woodford and these three other star managers lost their Midas touch?Interactive Investor
01-11-17Total Voting RightsRNS
01-11-17Broker Forecast - Kepler Cheuvreux issues a broker note on AstraZeneca PLCStockMarketWire
01-11-17AZ's tralokinumab disappoints in two trials StockMarketWire
01-11-17US FDA approves AstraZeneca's Calquence for MCLStockMarketWire
01-11-17AZ and Aspen complete anaesthetics deal StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AZN Editorial
  • Regulatory news feed for LSE:AZN Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account